Canaccord lowered the firm’s price target on Akoya Biosciences (AKYA) to $1.08 from $1.80 and keeps a Hold rating on the shares. The analyst said the target decrease reflects the current merger valuation with Quanterix (QTRX) but noted the company reported 1Q25 results that were below consensus estimates and the top-line decline in 1Q25 was primarily driven by a decrease in service and other revenue.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKYA:
- Cautious Hold Rating on Akoya Biosciences Amid Financial and Industry Challenges
- Quanterix price target lowered to $12 from $15 at Canaccord
- Quanterix shareholder issues statement on Akoya Biosciences merger pact
- Quanterix downgraded to Market Perform from Outperform at Leerink
- Akoya Biosciences and Quanterix Amend Merger Agreement